Abstract
The prevalence of osteoarthritis (OA) increases not only because of longer life expectancy but also because of the modern lifestyle, in particular physical inactivity and diets low in fiber and rich in sugar and saturated fats, which promote chronic low-grade inflammation and obesity. Adverse alterations of the gut microbiota (GMB) composition, called microbial dysbiosis, may favor metabolic syndrome and inflammaging, two important components of OA onset and evolution. Considering the burden of OA and the need to define preventive and therapeutic interventions targeting the modifiable components of OA, an expert working group was convened by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) to review the potential contribution of GMB to OA. Such a contribution is supported by observational or dietary intervention studies in animal models of OA and in humans. In addition, several well-recognized risk factors of OA interact with GMB. Lastly, GMB is a critical determinant of drug metabolism and bioavailability and may influence the response to OA medications. Further research targeting GMB or its metabolites is needed to move the field of OA from symptomatic management to individualized interventions targeting its pathogenesis.
| Original language | English |
|---|---|
| Article number | 100946 |
| Journal | Ageing Research Reviews |
| Volume | 55 |
| DOIs | |
| Publication status | Published - Nov 1 2019 |
Fingerprint
Keywords
- Dysbiosis
- Gut microbiota
- Inflammaging
- Modern diet
- Obesity
- Osteoarthritis
ASJC Scopus subject areas
- Biotechnology
- Biochemistry
- Ageing
- Molecular Biology
- Neurology
Cite this
Gut microbiota and osteoarthritis management : An expert consensus of the European society for clinical and economic aspects of osteoporosis, osteoarthritis and musculoskeletal diseases (ESCEO). / Biver, Emmanuel; Berenbaum, Francis; Valdes, Ana M.; Araujo de Carvalho, Islene; Bindels, Laure B.; Brandi, Maria Luisa; Calder, Philip C.; Castronovo, Vincenzo; Cavalier, Etienne; Cherubini, Antonio; Cooper, Cyrus; Dennison, Elaine; Franceschi, Claudio; Fuggle, Nicholas; Laslop, Andrea; Miossec, Pierre; Thomas, Thierry; Tuzun, Sansin; Veronese, Nicola; Vlaskovska, Mila; Reginster, Jean Yves; Rizzoli, René.
In: Ageing Research Reviews, Vol. 55, 100946, 01.11.2019.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Gut microbiota and osteoarthritis management
T2 - An expert consensus of the European society for clinical and economic aspects of osteoporosis, osteoarthritis and musculoskeletal diseases (ESCEO)
AU - Biver, Emmanuel
AU - Berenbaum, Francis
AU - Valdes, Ana M.
AU - Araujo de Carvalho, Islene
AU - Bindels, Laure B.
AU - Brandi, Maria Luisa
AU - Calder, Philip C.
AU - Castronovo, Vincenzo
AU - Cavalier, Etienne
AU - Cherubini, Antonio
AU - Cooper, Cyrus
AU - Dennison, Elaine
AU - Franceschi, Claudio
AU - Fuggle, Nicholas
AU - Laslop, Andrea
AU - Miossec, Pierre
AU - Thomas, Thierry
AU - Tuzun, Sansin
AU - Veronese, Nicola
AU - Vlaskovska, Mila
AU - Reginster, Jean Yves
AU - Rizzoli, René
PY - 2019/11/1
Y1 - 2019/11/1
N2 - The prevalence of osteoarthritis (OA) increases not only because of longer life expectancy but also because of the modern lifestyle, in particular physical inactivity and diets low in fiber and rich in sugar and saturated fats, which promote chronic low-grade inflammation and obesity. Adverse alterations of the gut microbiota (GMB) composition, called microbial dysbiosis, may favor metabolic syndrome and inflammaging, two important components of OA onset and evolution. Considering the burden of OA and the need to define preventive and therapeutic interventions targeting the modifiable components of OA, an expert working group was convened by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) to review the potential contribution of GMB to OA. Such a contribution is supported by observational or dietary intervention studies in animal models of OA and in humans. In addition, several well-recognized risk factors of OA interact with GMB. Lastly, GMB is a critical determinant of drug metabolism and bioavailability and may influence the response to OA medications. Further research targeting GMB or its metabolites is needed to move the field of OA from symptomatic management to individualized interventions targeting its pathogenesis.
AB - The prevalence of osteoarthritis (OA) increases not only because of longer life expectancy but also because of the modern lifestyle, in particular physical inactivity and diets low in fiber and rich in sugar and saturated fats, which promote chronic low-grade inflammation and obesity. Adverse alterations of the gut microbiota (GMB) composition, called microbial dysbiosis, may favor metabolic syndrome and inflammaging, two important components of OA onset and evolution. Considering the burden of OA and the need to define preventive and therapeutic interventions targeting the modifiable components of OA, an expert working group was convened by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) to review the potential contribution of GMB to OA. Such a contribution is supported by observational or dietary intervention studies in animal models of OA and in humans. In addition, several well-recognized risk factors of OA interact with GMB. Lastly, GMB is a critical determinant of drug metabolism and bioavailability and may influence the response to OA medications. Further research targeting GMB or its metabolites is needed to move the field of OA from symptomatic management to individualized interventions targeting its pathogenesis.
KW - Dysbiosis
KW - Gut microbiota
KW - Inflammaging
KW - Modern diet
KW - Obesity
KW - Osteoarthritis
UR - http://www.scopus.com/inward/record.url?scp=85071046539&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85071046539&partnerID=8YFLogxK
U2 - 10.1016/j.arr.2019.100946
DO - 10.1016/j.arr.2019.100946
M3 - Review article
C2 - 31437484
AN - SCOPUS:85071046539
VL - 55
JO - Ageing Research Reviews
JF - Ageing Research Reviews
SN - 1568-1637
M1 - 100946
ER -